Infographic: Antibody Cancer Therapy

An experimental technique removes T cells that aid in vitro tumor growth.

ruth williams
Ruth Williams

Ruth is a freelance journalist.

View full profile.

Learn about our editorial policies.

Mar 31, 2017



Tumors (purple cells) recruit abnormally high numbers of potently immune-suppressing Tregs, which repress effector T cells (1) and prevent cancer destruction. Addition of anti-TNFR2 monoclonal antibodies (2) targets and kills TNFR2-expressing Tregs, thereby boosting the activity of effector T cells, which attack the tumor (3). The antibodies can also directly kill tumor cells that express the TNFR2 receptor.

Read the full story.

Interested in reading more?

Infographic: Antibody Cancer Therapy

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?